<DOC>
	<DOCNO>NCT01440413</DOCNO>
	<brief_summary>This prospective , non-randomized study aim evaluate response neoadjuvant chemotherapy accord antitumor immune response localize breast cancer . 40 patient enrol study . They receive chemotherapy : 3 4 anthracycline cycle 3 4 FEC-100 cycle follow 3 4 taxane cycle . Trastuzumab add taxane HER2+/Neu+ patient . Then , patient operate receive adjuvant treatment depend investigator 's appreciation . Blood sample collect first day first chemotherapy cycle , first day third cycle , surgery , 6 month surgery case relapse . Tumor sample collect diagnosis much possible surgery . Patients follow 5 year .</brief_summary>
	<brief_title>Study Response Neoadjuvant Chemotherapy Based Antitumor Immune Response Localized Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histologically proven localize breast cancer require anthracycline chemotherapy +/ trastuzumab surgery Age &gt; 18 year Chemotherapy 3 anthracycline cycle begin ( doxorubicin epirubicin ) Any previous treatment cancer Performance Status &lt; = 1 Agreement conservation biological sample Covered medical insurance Signed write informed consent form Availability tumoral sample collect diagnosis Previous surgery breast cancer Already chemotherapy first blood sample Previous Antitumoral treatment Under immunosuppressive treatment Under corticoid 15 day enrollment History concomitant cancer except cure least 5 year History lymphoma breast sarcoma History chronic inflammatory disease autoimmune disease , hepatitis B C immune dysfunction disease ( include HIVpositive stage AIDS ) know History disease discrepant study Deprived liberty court administrative decision Pregnant breastfeed woman use effective birth control method woman childbearing potential</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>anti-tumor immune response</keyword>
	<keyword>neo-adjuvant chemotherapy</keyword>
	<keyword>relapse</keyword>
	<keyword>long term survival</keyword>
	<keyword>histo-pathological response</keyword>
	<keyword>tumor cell death</keyword>
	<keyword>tumor associate antigen</keyword>
	<keyword>Calreticulin</keyword>
	<keyword>Localized breast cancer</keyword>
</DOC>